Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: The LateTIME randomized trial

JAMA

Volumn 306, Issue 19, 2011, Pages 2110-2119

  Traverse, Jay H ^a,b   Henry, Timothy D ^a,b   Ellis, Stephen G ^c   Pepine, Carl J ^d   Willerson, James T ^e   Zhao, David X M ^f   Forder, John R ^d   Byrne, Barry J ^d   Hatzopoulos, Antonis K ^f   Penn, Marc S ^g   Perin, Emerson C ^e   Baran, Kenneth W ^h   Chambers, Jeffrey ⁱ   Lambert, Charles ^d,j   Raveendran, Ganesh ^b   Simon, Daniel I ^k   Vaughan, Douglas E ^l   Simpson, Lara M ^m   Gee, Adrian P ^o   Taylor, Doris A ^b   Cogle, Christopher R ^d   Thomas, James D ^c   Silva, Guilherme V ^e   Jorgenson, Beth C ^a   Olson, Rachel E ^a   Bowman, Sherry ^f   Francescon, Judy ^f   Geither, Carrie ^c   Handberg, Eileen ^d   Smith, Deirdre X ^e   Baraniuk, Sarah ^m   Piller, Linda B ^m   Loghin, Catalin ⁿ   Aguilar, David ^o   Richman, Sara ^o   Zierold, Claudia ^b   Bettencourt, Judy ^m   Sayre, Shelly L ^m   Vojvodic, Rachel W ^m   Skarlatos, Sonia I ^p   Gordon, David J ^p   Ebert, Ray F ^p   Kwak, Minjung ^p   Moyé, Lemuel A ^m   Simari, Robert D ^q   more..

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e ST LUKE S EPISCOPAL HOSPITAL   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Summa Cardiovascular Institute   (United States)

^h United Heart and Vascular Clinic   (United States)

ⁱ Mercy Hospital   (United States)

^j FLORIDA HOSPITAL   (United States)

^k UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^o BAYLOR COLLEGE OF MEDICINE   (United States)

^p NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^q MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ACUTE HEART INFARCTION; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW MONONUCLEAR CELL TRANSPLANTATION; CELL TRANSPLANTATION; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART LEFT VENTRICLE WALL MOTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; THROMBUS ASPIRATION;

EID: 81255208675     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1670     Document Type: Article

References (38)

1. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355 (12):1210-1221. (Pubitemid 44427445)
2. Huang RC, Yao K, Zou YZ, et al. Long term follow- up on emergent intracoronary autologous bone marrow mononuclear cell transplantation for acute inferior- wall myocardial infarction. Zhonghua Yi Xue Za Zhi. 2006;86(16):1107-1110. (Pubitemid 43950807)
3. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364(9429):141-148. (Pubitemid 38891685)
4. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: doubleblind, randomised controlled trial. Lancet. 2006; 367(9505):113-121. (Pubitemid 43077127)
5. Schächinger V, Erbs S, Elsässer A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27(23):2775- 2783.
6. Tendera M, Wojakowski W, Ruzyłło W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J. 2009;30(11):1313-1321.
7. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355 (12):1199-1209. (Pubitemid 44427444)
8. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J. 2011;32(14):1736-1747.
9. Traverse JH, McKenna DH, Harvey K, et al. Results ofaphase1,randomized, double-blind,placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction. Am Heart J. 2010;160(3):428-434.
10. Wöhrle J, Merkle N, Mailänder V, et al. Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol. 2010;105(6):804- 812.
11. Roncalli J, Mouquet F, Piot C, et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J. 2011;32(14):1748-1757.
12. Traverse JH, Henry TD, Vaughan DE, et al. Rationale and design for TIME: a phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J. 2009;158(3):356-363.
13. Traverse JH, Henry TD, Vaughan DE, et al. Late- TIME: a phase-II, randomized, double-blinded, placebo- controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010;37(4):412-420.
14. Miettinen JA, Ylitalo K, Hedberg P, et al. Determinants of functional recovery after myocardial infarction of patients treated with bone marrowderived stem cells after thrombolytic therapy. Heart. 2010;96(5):362-367.
15. Gee AP, Richman S, Durett A, et al. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy. 2010;12(5):684-691.
16. Simari RD, Moyé LA, Skarlatos SI, et al. Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res. 2010;3(1):30-36.
17. Martin-Rendon E, Brunskill SJ, Hyde CJ, et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008;29(15):1807-1818.
18. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. JMol Cell Cardiol. 2010; 48(3):504-511.
19. Wang X, Takagawa J, Lam VC, et al. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response. Sci Transl Med. 2011;3(100): ra90.
20. Higuchi T, Bengel FM, Seidl S, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res. 2008;78(2):395-403. (Pubitemid 351556104)
21. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008;58(2):88-111.
22. Wojakowski W, Landmesser U, Bachowski R, Jadczyk T, Tendera M. Mobilization of stem and progenitor cells in cardiovascular diseases. Leukemia. doi:10.1038/leu2011.184.
23. Leone AM, Rutella S, Bonanno G, et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005;26(12):1196-1204. (Pubitemid 40863126)
24. Massa M, Rosti V, Ferrario M, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2005;105(1):199-206. (Pubitemid 40053083)
25. Askari AT, Unzek S, Popovic ZB, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362(9385):697-703. (Pubitemid 37101067)
26. Schächinger V, Aicher A, Döbert N, et al. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation. 2008; 118(14):1425-1432.
27. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103(23): 2776-2779. (Pubitemid 32550062)
28. Cogle CR, Pettway R, Zierold C, et al. Time from onset to acute myocardial infarction negatively influences bone marrow cell function: preliminary data from the NHLBI CCTRN ancillary studies [abstract]. Circulation. 2009;120(18):S1132.
29. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829):701-705. (Pubitemid 32290358)
30. Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A. 2005;102(32):11474- 11479.
31. Yoon YS, Wecker A, Heyd L, et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest. 2005;115(2):326-338. (Pubitemid 40385474)
32. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007; 167(10):989-997. (Pubitemid 46835786)
33. Lipinski MJ, Biondi-Zoccai GG, Abbate A, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and metaanalysis of controlled clinical trials. J Am Coll Cardiol. 2007;50(18):1761-1767. (Pubitemid 47600592)
34. Traverse JH, Henry TD, Moye' LA. Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? an analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after STsegment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging.Am Heart J. 2011;162(4):671-677.
35. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J. 2007;28(6):766-772. (Pubitemid 46439231)
36. van Beem RT, Hirsch A, Lommerse IM, et al. Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarction. EuroIntervention. 2008;4(1):133-138.
37. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, doseescalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277-2286.
38. Perin EC, Dib N, DeMaria A, et al. A phase II doseescalation study of allogenic mesenchymal precursor cells in patients with ischemic and non-ischemic heart failure. Paper presented at: 2011 Scientific Sessions of the American Heart Association; November 14, 2011; Orlando, FL.